1	A common 1.6 Mb Y-chromosomal inversion predisposes to subsequent deletions and severe
2	spermatogenic failure in humans
3	
4	Pille Hallast ^{1,2*} , Laura Kibena ¹ , Margus Punab ^{3,4} , Elena Arciero ² , Siiri Rootsi ⁵ , Marina Grigorova ¹ ,
5	Rodrigo Flores ⁵ , Mark A. Jobling ⁶ , Olev Poolamets ³ , Kristjan Pomm ³ , Paul Korrovits ³ , Kristiina
6	Rull ^{1,4,7} , Yali Xue ² , Chris Tyler-Smith ² and Maris Laan ¹ *
7	
8	¹ Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, 50411, Estonia
9	² Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK
10	³ Andrology Unit, Tartu University Hospital, Tartu, 50406, Estonia
11	⁴ Institute of Clinical Medicine, University of Tartu, Tartu, 50406, Estonia
12	⁵ Institute of Genomics, Estonian Biocentre, University of Tartu, Tartu, 51010, Estonia
13	⁶ Department of Genetics & Genome Biology, University of Leicester, Leicester, LE1 7RH, UK
14	⁷ Women's Clinic, Tartu University Hospital, Tartu, 50406, Estonia
15	* Corresponding authors
16	
17	
18	Correspondence:
19	Pille Hallast, pille.hallast@ut.ee; Tel: +372 737 5009
20	Maris Laan, maris.laan@ut.ee; Tel: +372 737 5008
21	
22	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 Abstract

24 Male infertility is a prevalent condition, concerning 5-10% of men. So far, only some recurrent genetic 25 factors have been described as confident contributors to spermatogenic failure. Here, we report the first 26 re-sequencing study of the Y-chromosomal Azoospermia Factor c (AZFc) region combined with gene 27 dosage and Y-haplogroup determination. In analysing 2.324 Estonian men, we uncovered a novel 28 structural variant as a high-penetrant risk factor to male infertility. The Y lineage R1a1-M458, reported 29 at >20% frequency in several European populations, carries a fixed ~1.6 Mb long r2/r3 inversion 30 destabilizing the AZFc region and predisposing to recurrent microdeletions. Such complex 31 rearrangements were significantly enriched among severe oligozoospermia cases. The carrier vs non-32 carrier risk to spermatogenic failure was increased 8.6-fold ($p = 6.0 \times 10^{-4}$). The finding contributes to 33 improved molecular diagnostics and clinical management of infertility. Carrier identification in young 34 age will facilitate timely counselling and reproductive decision-making. 35

- 36
- 37 **Keywords:** idiopathic male infertility; Y-chromosomal *AZFc* region; re-sequencing; *gr/gr* deletion;
- complex structural rearrangements; Y haplogroup R1a1-M458; DAZ, BPY2, CDY1 dosage and variants 38
- 39

40

Introduction 41

42 The diagnosis of male factor infertility due to abnormal semen parameters concerns $\sim 10\%$ of men (1, 43 2). In today's andrology workup $\sim 60\%$ of patients with spermatogenic failure remain idiopathic (3). 44 Among the known causes, the most widely considered genetic factors are karyotype abnormalities (up 45 to 17% of patients) and recurrent de novo microdeletions of the Y-chromosomal AZFa (~0.8 Mb), AZFb 46 (~6.2 Mb) and AZFc (~3.5 Mb) regions (2–10%)(3-5). For more than 15 years, testing for AZF deletions 47 has been strongly recommended in the diagnostic workup for infertility patients with sperm 48 concentration $<5 \times 10^{6}$ /ml (6, 7). Most deletion carriers represent patients with either azoospermia (no 49 sperm) or cryptozoospermia (>0–1 million sperm/ejaculate) (3, 8, 9). The most prevalent deletion type 50 is AZFc (~80%), followed by the loss of AZFa (0.5–4%), AZFb (1–5%) and AZFbc (1–3%) regions 51 (Figure 1A). Excess of recurrent AZFc deletions is promoted by the region's complex genomic 52 structure comprised of long direct and inverted amplicons of nearly identical DNA segments that lead 53 to aberrant meiotic rearrangements in gametogenesis (10, 11) (Figure 1B). The AZFc full deletions 54 remove all the multi-copy DAZ (deleted in azoospermia 1), BPY2 (basic charge Y-linked 2) and CDY1 55 (chromodomain Y-linked 1) genes that are expressed in a testis-enriched manner and considered 56 important in spermatogenesis (Figure 1C).

57 The palindromic structure of the AZFc region also facilitates partial deletions that are rather frequently 58 detected in the general population (12-15). The most prevalent partial deletion types, named after the 59 involved amplicons as g(reen)-r(ed)/g(reen)-r(ed) (lost segment ~1.6 Mb) and b(lue)2/b(lue)3 (~1.8 60 Mb) reduce the copy-number of DAZ, BPY2 and CDY1 genes by roughly 50% (Figure 1B-C, Figure 61 **S1**). The published data on the contribution of $\frac{gr}{gr}$ and $\frac{b2}{b3}$ deletions to spermatogenic failure are 62 inconsistent. In European populations, the carrier status of the gr/gr deletion increases a risk to low 63 sperm counts ~ 1.8 -fold (14, 16, 17). Its more variable effect on spermatogenesis has been shown in 64 Middle Eastern and Asian populations, where the gr/gr deletion is completely fixed in some Y lineages, 65 e.g. haplogroups D2 and Q1a that are common in Japan and some parts of China (18, 19). In contrast, 66 the b2/b3 deletion appears to be a risk factor for spermatogenic impairment in several East Asian and 67 African, but not in European or South Asian populations (20, 21). Notably, the b2/b3 deletion is

68 completely fixed in Y haplogroup N3 that has a high frequency (up to 90% in some populations) in 69 Finno-Ugric, Baltic and some Turkic-speaking people living in Northern Eurasia (14, 15, 22). Thus, it 70 is unlikely that the carriership of a gr/gr or b2/b3 deletion per se has an effect on male fertility potential. 71 It has been proposed that this broad phenotypic variability may be explained by the diversity of $\frac{gr}{gr}$ 72 and b2/b3 deletion subtypes (23). Y chromosomes carrying partial AZFc deletions may differ for the 73 content, dosage or genetic variability of the retained genes, the overall genetic composition reflected by 74 phylogenetic haplogroups or the presence of additional structural variants. Only limited studies have 75 analyzed the subtypes of gr/gr or b2/b3 deletions and no straightforward conclusions have been reached 76 for their link to spermatogenic failure (17, 24, 25).

77 The current study represents the largest in-depth investigation of AZFc partial deletions in men recruited by a single European clinical center. We analysed 1,190 Estonian idiopathic patients with male factor 78 79 infertility in comparison to 1.134 reference men from the same population, including 810 subjects with sperm parameter data available. Y chromosomes carrying gr/gr or b2/b3 deletions were investigated 80 81 for additional genomic rearrangements, Y-chromosomal haplogroups, dosage and sequence variation 82 of the retained DAZ, BPY2 and CDY genes. The study aimed to determine the role and contribution of 83 gr/gr and b2/b3 deletion subtypes in spermatogenic failure and to explore their potential in the clinical 84 perspective.

85

86 **Results**

87 Enrichment of *gr/gr* deletions in Estonian idiopathic infertile men with reduced sperm counts

The study analyzed 1,190 Estonian men with idiopathic infertility (sperm counts $0 - 39 \times 10^6$ /ejaculate) and a reference group comprised of 1,134 Estonian men with proven fatherhood (n=635) or representing healthy young men (n=499) (**Table 1, Table S1**). For all 2,324 study subjects, complete *AZFa, AZFb* and *AZFc* deletions were excluded.

The partial *AZFc* deletions identified were gr/gr (n=46), b2/b3 (n=756) and b1/b3 (n=1, reference case) (**Table 2**). A statistically significant excess of gr/gr deletions was detected in idiopathic male infertility patients (2.7%; n=32/1,190) compared to reference cases (1.2%; n=14/1,134) (Fisher's exact test,

95 p=0.016; OR = 2.2 [95% CI 1.2 - 4.2]) (Figure 1D, Table S2). The highest frequency of gr/gr deletion 96 carriers (6.8%, n=6/88) was detected in cryptozoospermia cases (sperm count $>0 - 1 \ge 10^6$ /ejaculate). 97 However, in the reference group and rological parameters of men with or without the $\frac{gr}{gr}$ deletion did 98 not differ (**Table S3**). All 10 reference men with the gr/gr deletion and available andrological data were 99 normozoospermic (220.3 [74.2-559.0] x 10⁶ sperm/ ejaculate). Also their other andrological parameters 100 were within the normal range, overlapping with those of the subjects without a gr/gr deletion. 101 The patient and the reference groups exhibited similar prevalence of b2/b3 deletions (388/1190, 32.6%) 102 vs. 367/1134, 32.4%; Fisher's exact test, p=0.8). No apparent clinically meaningful genetic effects on 103 andrological parameters were observed in either of the study groups (Table S3-S4). 104

105 Significant overrepresentation of Y lineage R1a1-M458 in gr/gr deletion carriers

106 The Y-chromosomal haplogroups determined in 31 patients and 13 reference men carrying a gr/gr107 deletion represented 20 different lineages (patients, 17; reference men, 10; Figure 2A, Table S5a). 108 Combining the phylogenetic context with the data on exact missing DAZ and CDY1 gene copies (see 109 *below*) revealed that the *gr/gr* deletion events in 44 analyzed cases must have independently occurred 110 at least 26 times. About two-thirds of these Y chromosomes belonged to haplogroup R1, whereas the 111 rest represented A1b, G, I and J lineages. Notably, there was a highly significant overrepresentation of 112 Y chromosomes belonging to lineage R1a1-M458 in the gr/gr deletion carriers compared to the known Estonian population frequency (22.7% vs 5.1%; Fisher's exact test, $p=5.3 \times 10^{-4}$, OR = 5.5 [95% CI 113 114

2.2-13.7]; Figure 2B, Table S5b) (26).

115 Nearly all (99.4%) Estonian cases with the b2/b3 deletion belonged to the Y haplogroup N3, in which 116 this event is fixed (13, 15). The most commonly detected sub-lineage was N3a3a-L550 (~51% of 436 117 typed chromosomes) and in total 15 different haplogroups that had diverged after the b2/b3 deletion 118 event in the common ancestor of N3 were present in Estonian men (Figure 2C, Table S6). b2/b3 Y 119 chromosomes representing non-N3 lineages were detected in two patients and three reference men. 120 Lineage typing was possible for three of them, who carried either K-M9 (one patient) or 121 R1a1a1b1a1a1c-CTS11962.1 (one patient and one reference case).

122

123 Increased prevalence of *b2/b3* deletion followed by *b2/b4* duplication in infertile men

124 The expected retained copy number of DAZ, BPY2 and CDY1 genes consistent with the typical gr/gr 125 deletion was found in 37/44 (~84%) cases (Figure 2A, Table 2, Table S7). Three patients and three 126 reference men carried a secondary b2/b4 duplication adding one or more amplicons of [two DAZ – two 127 BPY2 – one CDY1] genes with no apparent effect on infertility status (Fisher's exact test, p=0.34). 128 Notably, four of six samples with secondary b2/b4 duplication events were identified in haplogroup I. 129 Similarly, 78.5% of patients and 84.3% reference men with the b2/b3 deletion presented gene dosage 130 consistent with the typical deletion (Figure 2C, Table 2, Table S7-S8). Indicative of recurrent 131 secondary events, one or more b2/b4 duplications of [two DAZ – one BPY2 – one CDY1] genes were 132 identified in 13 haplogroups, including non-N3 lineages K-M9 and R1a1a1b1a1a1c-CTS11962.1. 133 Although secondary b2/b4 duplications were detected with significantly higher prevalence in patients 134 compared to the reference men (n=78/382, 20.4% vs n=35/249, 14.1%; Fisher's exact test, p=0.026, 135 OR = 1.57 [95% CI 1.02 - 2.42]), no consistent effect of increased gene copy number on andrological 136 parameters was observed (Tables S3-S4). Reference men with b2/b4 duplication compared to subjects 137 with no AZFc rearrangements showed a trend for lower FSH (median 2.3 [5-95% range 1.4-7.5] vs 3.2 138 [1.3-7.1] IU/L; P<0.05) and LH (3.1 [1.7-5.0] vs 3.8 (1.7-7.2) IU/L; P<0.05). Additionally, in eight 139 subjects with AZFc partial deletions, further atypical Y-chromosomal genomic rearrangements were 140 detected, but also with no clear evidence for a phenotypic effect (Table 2, Table S7). 141 The data gathered from this analysis thus suggest that the dosage of DAZ, BPY2 and CDY1 genes does

142 not play a major role in modulating the pathogenic effect of the gr/gr and b2/b3 deletions.

143

144 No specific DAZ or CDY1 gene copy is lost in men with spermatogenic failure

145 The major b2/b3 deletion subtype in both patients (99.7%) and reference cases (98.1%) was the loss of 146 DAZ3-DAZ4-CDY1a genes, whereas the most frequent gr/gr deletion subtypes were the loss of DAZ1-147 DAZ2-CDY1a (41.9%, 18/43 cases) and DAZ1-DAZ2-CDY1b (25.6%, 11/43 cases) combinations 148 (Figure 2A, Table S9-S10). The observed prevalence of the major gr/gr subtypes was concordant with 149 the published data on other European populations (42.5% and 25.5%, respectively; (17)). As these gr/gr150 deletion subtypes are prevalent in the reference group (total 11 of 13, 84.6%), their major role in

151 spermatogenic impairment can be ruled out. As a novel insight, a subset of these Y chromosomes 152 showed lineage-specific loss of some exon 7 subtypes of the retained DAZ4 gene (Figure S2; Table 153 **S10**). All five exons 7Y were missing in the Y chromosomes with the DAZ1-DAZ2-CDY1a deletion 154 that had occurred in sub-lineages of the R1a1a1b1a2 haplogroup (9/31 patients, 3/13 reference men). 155 The exon 7F was lost in haplogroup I1 and its sub-lineages (5/31, 2/13) carrying the DAZ1-DAZ2-156 CDY1b deletion. There was no evidence that loss of DAZ4 exons 7Y or 7F has any phenotypic 157 consequences. Most likely, this observation reflects gene conversion events from DAZ3 to DAZ4 as the 158 former lacks both, exons 7Y and 7F.

159 Taken together, our findings indicate that neither the loss of the *DAZ1-DAZ2* nor the *DAZ3-DAZ4* gene

160 pair, combined with either a CDY1a or CDY1b gene, directly causes spermatogenic failure.

161 Interestingly, no Y chromosomes were observed with fewer than two retained *DAZ* genes.

162

163 Y lineage R1a1-M458 carries a fixed *r2/r3* inversion predisposing to recurrent deletions

164 Novel atypical gr/gr and b2/b3 deletion subtypes with the loss of an unusual DAZ gene pair were 165 identified (Figure 2A, Table 2, Table S9-S11). Eight patients and two reference cases with a gr/gr 166 deletion were missing DAZ2-DAZ4 genes. Loss of DAZ1-DAZ3 genes followed by a subsequent b2/b4167 duplication event was identified in one infertile and one reference case with either $\frac{gr}{gr}$ or $\frac{b2}{b3}$ 168 deletion, respectively. All but one subject with this atypical pair of lost DAZ genes belonged to the Y 169 haplogroup R1a1-M458 and its sub-lineages, significantly enriched in gr/gr deletion carriers (Figure 170 2B, Table S5b). The most parsimonious explanation to explain the simultaneous deletion of either 171 DAZ1-DAZ3 or DAZ2-DAZ4 genes is a preceding ~1.6 Mb long inversion between the r(ed) and r(ed) 3 172 amplicons (Figure 3A). This new inverted structure might be more susceptible to recurrent deletions 173 as it has altered the internal palindromic structure of AZFc region. In r2/r3 inversion chromosomes, the 174 largest palindrome P1 is almost completely lost and the size of the palindrome P2 is greatly expanded 175 by positioning the homologous g1/g2 segments in an inverted orientation. The r2/r3 inversion is 176 consequently expected to destabilize the AZFc region as several long DNA amplicons with highly 177 homologous DNA sequence are positioned in the same sequence orientation (b2, b3 and b4; g2 and g3; 178 v1 and v3). Therefore, they are prone to non-allelic homologous recombination mediating recurrent

chromosomal haplogroup, the detected r2/r3 inversion must have occurred only once in the common

179 deletions and duplications. Since these atypical deletion subtypes were identified only in a specific Y-

181 ancestor of R1a1-M458 sub-lineages. One patient with the loss of *DAZ2-DAZ4* carried haplogroup

182 R1a1a1-M417, an ancestral lineage to R1a1-M458 (Figure 2A). However, lineage R1a1a1-M417 is not

183 fixed for this inversion since its other sub-lineage, R1a1a1b1a2, does not carry it and any subsequent

184 inversion restoring the exact original *AZFc* structure is not credible. The more parsimonious explanation

185 is that the inversion occurred in a sub-lineage of R1a1a1-M417 that has to be yet determined.

186 Based on the Y-chromosomal phylogenetic data, one additional patient was identified as an obligate

187 carrier of the r2/r3 inversion as his Y chromosome represents the lineage R1a1a1b1a1a1c-CTS11962.1

188 that was also identified in two cases with the r2/r3 inversion. This patient exhibited signs of unusual

deletion and duplication events in the *AZFc* region as he carried six *DAZ*, four *BPY2* and three copies

190 of the *CDY1* gene (Figure 2B, Table 2, Table S8).

Among the analyzed 2,324 men, 13 cases with the complex *AZFc* rearrangement combining r2/r3inversion with a subsequent deletion, represented 0.6% (**Table 3**). Considering the reported population prevalence of R1a1-M458 lineage in Estonians (5.1%; (26)), the estimated number of subjects representing this Y lineage in the study group was ~119. Thus, approximately one in ten chromosomes with the r2/r3 inversion had undergone a subsequent deletion event (13/119, 11%).

196

180

197 *r2/r3* inversion promotes recurrent deletions that lead to severe oligoasthenoteratozoospermia

198 Idiopathic infertility cases carrying the r2/r3 inversion with a subsequent deletion in the AZFc region 199 (n=10) exhibited extremely low sperm counts compared to subjects without any AZFc deletions (median 200 2.0 vs 12.5 x 10⁶/ejaculate; Wilcoxon test, p=0.011) (Figure 3B, Figure S3, Table S3). Nine of 10 men 201 showed severe spermatogenic failure (total sperm counts $<10 \times 10^{6}$ /ejaculate), either azoo- (n=1), 202 crypto- (n=3) or severe oligozoospermia (n=5) (Table S10-S11). They also showed consistently the 203 poorest sperm concentration (median 1.0×10^6 /ml) and progressive motility (13%), as well as the lowest 204 semen volume (2.3 ml) compared to the rest of analyzed infertile men. The data suggests that extreme 205 oligoasthenoteratozoospermia (OAT) observed in these subjects was due to the severely affected

206 process of spermatogenesis, whereas their testicular volume and hormonal profile were within the 207 typical range of male factor infertility cases (Figure 3C).

- When all the men with andrological data (n=2,000) were stratified based on sperm counts, there was a highly significant enrichment of the r2/r3 inversion with a subsequent deletion in men with severe spermatogenic failure (sperm counts 0 – 10 x 10⁶) compared to the rest (1.7% vs 0.2%, Fisher's exact test, $p=6.0 \times 10^{-4}$, OR=8.6 [95% CI 2.3 – 31.8]; **Table 3**). The estimated number of phenotyped subjects
- representing the Y haplogroup R1a1-M458 with the fixed r2/r3 inversion was 102 (based on population
- prevalence 5.1%; (26)). Among carriers of this Y lineage, 33.7% of men with sperm counts 0–10 x 10^6

214 (9/27), but only 4.0% with sperm counts >10 x 10^{6} (3/72) had undergone a subsequent AZFc partial

215 deletion (Fisher's exact test, $p=3.0 \times 10^{-4}$, OR = 12.0 [95% CI 2.9 - 48.9]).

216 Only three reference cases carried a Y chromosome with the r2/r3 inversion with a subsequent AZFc 217 partial deletion. At the time of phenotyping, all three subjects were younger (aged 18, 21 and 23 years) 218 than the variant carriers in the idiopathic infertility group (median 32.4, range 26-51 years) (Table S11). 219 The only reference subject with this complex AZFc rearrangement, but unaffected sperm analysis was 220 the youngest (18 years). Notably, another reference man (23 years) with andrological data would 221 actually be classified, based on WHO guidelines (27), as an oligozoospermia case (sperm concentration 12×10^{6} /ml vs threshold 15 x 10^{6} /ml). Also, his total sperm counts (39.4 x 10^{6} /ejaculate) represented a 222 223 borderline value.

224

225 Sequence diversity of the retained *DAZ*, *BPY2* and *CDY* genes is extremely low and has no 226 detectable effect on sperm parameters

The re-sequenced retained *DAZ1-4*, *BPY2* and *CDY1-2* genes were characterized by extremely low nucleotide variability in all Y-chromosomal lineages and deletion subtypes (**Table S12**). For 476 samples (gr/gr, n=40; b2/b3, n= 436) re-sequenced for the >94 kb region, a total of 42 variants were identified with median 0.8 variants/kb and maximum two variants per individual. Most of them were previously undescribed (41), singletons (31) and/or non-coding SNVs/short indels (36) (**Table S13**). The *CDY2a-CDY2b* genes harbored only one variable site, whereas *DAZ1-DAZ2* carried 24 or 26 SNVs/indels. Most variants appeared paralogous as both the reference and alternative alleles were

identified. Among the four detected missense variants, CDY1b p.T419N was fixed in all three *CDY1b*

235 copies present on the Y chromosome with the b2/b3 deletion plus b2/b4 duplications that represented

- an oligozoospermia case. However, the effect of this conservative substitution is unclear.
- 237 There was thus no evidence that the sequence variation in *DAZ*, *BPY2* and *CDY* genes has any effect
- 238 on infertility related parameters in the subjects examined.
- 239

240 **Discussion**

241 We conducted a comprehensive investigation of partial deletion subtypes of the Y-chromosomal AZFc 242 region in 2,324 Estonian men, approximately half with idiopathic spermatogenic impairment (n=1,190) 243 in comparison to the reference group (n=1,134). Importantly, 2,000 men had undergone full and 244 uniformly conducted andrological workup at a single clinical center, facilitating fine-scale genotype-245 phenotype analysis. Previously, no study had undertaken re-sequencing of the retained DAZ, BPY2 and 246 CDY genes along with the assessment of the Y haplogroup, dosage and retained/deleted genes in the 247 gr/gr or b2/b3-deleted chromosomes in both infertile men and controls. Concordant with reports from 248 other European populations, the gr/gr, but not the b2/b3 deletion, is a risk factor for spermatogenic 249 impairment in Estonian men with >2-fold increased susceptibility to infertility (Figure 1D). However, 250 the gathered data on the large group of reference men in the current study demonstrated the existence 251 of Y chromosomes carrying a gr/gr deletion without any documented effect on andrological parameters 252 (Table S3). As a novel finding, the study uncovered complex AZFc rearrangements within a specific Y 253 haplogroup, R1a1-M458 and its sub-lineages, causing severe spermatogenic failure in the majority of 254 carriers (Figure 3, Table 3). This Y lineage has undergone a ~ 1.6 Mb r2/r3 inversion in the AZFc 255 region that has disrupted the structure of the palindromes P1 and P2, promoting subsequent recurrent 256 deletions and consequently, severely impaired the process of spermatogenesis.

257 Consistent with key early observations (*14, 17, 23*), this study supports the recurrent nature and high 258 subtype diversity of the *AZFc* partial losses that are currently considered jointly under the umbrella 259 term 'gr/gr deletions'. The 44 detected gr/gr deletions in our study sample were estimated to have 260 originated independently at least 26 times across the Y phylogenetic tree and include seven different

combinations of DAZ and CDY1 gene losses. Apparently, there is a substantial undescribed 261 262 heterogeneity in the spread and structure of *gr/gr* deletions that in turn results in phenotypic variability of the genetic effects. Unexpectedly, one in four Estonian gr/gr deletion carriers belonged to the Y-263 264 chromosomal haplogroup R1a1-M458 (and its sub-lineages) (Figure 2A-B; 22.7% vs 5.1% reported as 265 the Estonian population frequency (26)). Notably, a previous study has reported a significant 266 enrichment of the haplogroup R1a (ancestral lineage to the R1a1-M458) among gr/gr-deleted chromosomes in the Polish population (14), which has a high prevalence, 25%, of R1a1-M458 (26) 267 268 (Table S14). All the Estonian gr/gr cases and also additional b2/b3 deletion chromosomes representing 269 this Y lineage carried unusual retained DAZ gene pairs (DAZ1-DAZ3 or DAZ2-DAZ4) in combination 270 with either *CDY1a* or *CDY1b* gene copy (Figure 2). These complex *AZFc* rearrangements were best 271 explained by a preceding (and apparently fixed in R1a1-M458) ~1.6 Mb inversion between the 272 homologous r2 and r3 amplicons, followed by recurrent secondary partial AZFc deletions (Figure 3A). 273 The latter are facilitated by large ampliconic segments positioned in the same orientation. Inversions in 274 the AZFc region are not uncommon, but none of the previously described inversions is expected to 275 substantially disrupt the core palindromic structure of the AZFc region (Figure S1) (13, 23). In contrast, 276 the r2/r3 inversion disrupts the structure of palindrome P1 and expands the size of the P2 palindrome 277 more than two-fold (Figure 3A). The critical role of intact P1-P2 palindromes in the AZFc structure is 278 supported by the observation that no Y chromosomes have been described with a single DAZ gene copy, 279 whereas the inverted DAZ gene pairs form the 'heart' of both P1 and P2.

280 As a likely scenario, this complex AZFc rearrangement may predispose to spermatogenic impairment 281 through substantial destabilization of the intra-chromosomal structure affecting meiotic recombination and chromosomal segregation. Among 12 Estonian subjects carrying the AZFc r2/r3 inversion followed 282 283 by partial deletions and with available data for sperm counts, nine cases exhibited severe spermatogenic 284 failure, two had moderate oligozoospermia and only one case (aged 18 years) was normozoospermic 285 (Figure 3B-C). This represented ~8-9-fold enrichment of this complex rearrangement among men with severely reduced sperm counts $(0 - 10 \times 10^6; \text{Table 3})$. This genetic effect was observed specifically 286 287 on the effectiveness of spermatogenesis, whereas the measurements of bitesticular volume and 288 reproductive hormone levels did not stand out among the rest of analyzed infertile men. To our

knowledge, no other Y-lineage specific risk variants for spermatogenic impairment have been reported so far. Previously, the *DAZ2-DAZ4* deletion had been shown as a high-risk factor for male infertility in the Tunisian population, but the Y haplogroups of those subjects was not investigated (*24*). The survival of such a high-risk lineage in the population seems at first sight surprising, but may be accounted for by its possible age-specific effects on spermatogenesis, which may be exacerbated by the recent general decline in sperm count (*28*). In the past, this lineage may not have been disadvantageous.

295 This study outcome has notable clinical implications for the improvement of molecular diagnostics and 296 reducing the proportion of idiopathic male factor infertility cases. In Northern and Central Europe, the 297 prevalence of R1a1-M458 haplogroup carrying the r2/r3 inversion ranges from ~1% in the Netherlands 298 and Denmark to ~2-5% in Austria, Hungary, Germany, Baltics and most Balkan countries, whereas it 299 is widespread in Slavic populations and carried by 12-26% of men (Figure 4, Table S14)(26). In these 300 populations, recurrent secondary AZFc partial deletions on Y chromosomes representing the R1a1-301 M458 haplogroup (and its sub-lineages) may potentially explain from 0.3% up to ~9% of cases 302 presenting severe spermatogenic impairment (sperm counts <10 million per ejaculate). Further studies 303 in other populations and large samples of patients and normozoospermic controls are required to fully 304 establish the value of extending the current recommended testing of Y-chromosomal deletions by including the analysis of this novel Y-lineage-specific pathogenic AZFc rearrangement (a detailed 305 306 protocol is provided in Supplemental Subjects and Methods).

307 The evidence from the literature has shown that the increased prevalence of either $\frac{gr}{gr}$ or $\frac{b2}{b3}$ 308 deletions in infertility cases appears to be population-dependent (16, 20). It can be speculated that also 309 in other populations some specific Y lineages may carry AZFc structural variants that in combination 310 with partial deletions (or other rearrangements) predispose to chromosomal instability in the complex 311 process of spermatogenesis involving multiple well-coordinated cell divisions. So far, the largest 312 conducted study on the Y-chromosomal phylogeny of gr/gr deletion carriers included 152 infertile 313 subjects representing seven countries with different population genetic structures (17). However, the 314 number of cases per population was low and the study included only 17 fertile men. Also, the study did 315 not include fine-scale analysis of Y sub-lineages and the retained gene content. Long-range re-316 sequencing of the whole AZFc region in large numbers of men would be the preferred approach to

317 uncover its structural complexity. Additional pathogenic AZFc rearrangements may also exist among 318 Estonian infertile men. When omitting the cases carrying a gr/gr deletion at the r2/r3 inversion 319 background, a non-significant enrichment of the remaining gr/gr deletion chromosomes can be 320 observed in patients compared to reference men (1.9 vs 1.1%, p < 0.1; Table 2).

321 In addition to the main finding, our deep re-sequencing dataset revealed that neither the dosage, sequence variation nor exact copy of the retained DAZ, BPY2 and CDY1 gene showed any detectable 322 323 effect on spermatogenic parameters. All chromosomes with AZFc partial deletions exhibit extremely 324 low overall sequence variation of the retained DAZ, BPY2 and CDY genes. This observation is 325 consistent with previous reports showing low levels of genetic diversity of the human Y chromosome 326 (29) and suggesting that novel variants may be rapidly removed by active gene conversion among Y-327 chromosomal duplicate genes or selective constraint (30-32). Among the re-sequenced 382 328 chromosomes with b2/b3 deletions, no pathogenic mutations were detected in the single retained BPY2 329 and *CDY1* gene copies. At the same time, the high rates of large structural rearrangements and copy 330 number variation in the Y chromosome are well established, contrasting with low levels of sequence 331 variation (19, 33). One in five or six Estonian Y chromosomes with gr/gr and b2/b3 deletions had 332 undergone secondary rearrangements with no apparent effect on tested andrological parameters and 333 fertility potential (Table 2). In the literature, the data about the effects of secondary duplications after 334 an initial AZFc partial deletion on sperm parameters are inconclusive. Some studies have suggested 335 increased pathogenicity (34-38), whereas others have reported neutral or even positive effects on 336 spermatogenesis (17, 39-41). However, further copy number reductions in this genomic region appear 337 to be very rare - none of the 44 gr/gr or 631 b2/b3 deletion carriers were identified with further 338 reductions beyond what is expected from the initial deletion.

339 In summary, we have undertaken a comprehensive study of the carriers of AZFc partial gr/gr and b2/b3340 deletions, and uncovered high levels of structural variation in the AZFc locus, but low sequence 341 diversity of the coding genes within the region. As a major finding, we discovered a large inversion 342 specific to the Y lineage R1a1-M458 that represents a hotspot for subsequent AZFc partial deletions. 343 Men carrying Y chromosomes with this complex rearrangement have >10-fold increased risk of severe 344 spermatogenic failure, but the consequences of this risk could be potentially alleviated by early

345 identification of the variant carriers and facilitating the storage of their sperm samples. Our study results 346 thus have the potential to improve clinical diagnostics and management of idiopathic impaired 347 spermatogenesis in a significant fraction of men originating from Northern and Central European 348 populations.

349

350 Subjects and Methods

351 Ethics statement

The study was approved by the Ethics Review Committee on Human Research of the University of Tartu, Estonia (permissions 146/18, 152/4, 221/T-6, 221/M-5, 272/M-13, 267M-13, 286M-18, 288M-13), and sequencing/genotyping was approved at the Wellcome Sanger Institute under WTSI HMDMC 17/105. Written informed consent for evaluation and use of their clinical data for scientific purposes was obtained from each person prior to recruitment. All procedures and methods have been carried out in compliance with the guidelines of the Declaration of Helsinki.

358

359 Study subjects

360 Patients with idiopathic spermatogenic impairment (n=1,190) were recruited at the Andrology Centre 361 at Tartu University Hospital (AC-TUH) in 2003-2015 (PI: M. Punab). Included cases showed reduced 362 sperm counts ($<39 \times 10^6$ /ejaculate) in at least two consecutive semen analyses (27). Recruitment and 363 sampling, semen analyses and hormone assays and definition of idiopathic cases have previously been 364 described in detail (3). Men with known causes of male infertility detected during routine diagnostic 365 workup were excluded, e.g. cryptorchidism, testicular cancer, orchitis/epididymitis, mumps orchitis, 366 testis trauma, karyotype abnormalities and complete Y-chromosomal microdeletions. The final 367 idiopathic infertility group included 104 azoospermia (no sperm), 88 cryptozoospermia (sperm counts >0-1 x 10⁶/ejaculate), 319 severe oligozoospermia (1-10 x 10⁶) and 679 moderate oligozoospermia 368 369 $(10-38 \times 10^6)$ cases (Table 1, Table S1).

The reference sample of Estonian men (n=1,134) comprised healthy young men (n=499) and subjects with proven fatherhood (n=635) (**Table 1, Table S1**). The cohort of 'Estonian young men' (n=499) was

recruited at the AC-TUH in 2003-2004 (PI: M. Punab), representing a healthy male group with median age 18.6 (17.2-22.9) years at the time of recruitment (*42*). The subgroup of 'Partners of pregnant women' (n=324) includes male partners of pregnant women, recruited in 2010-2014 at the Tartu University Hospital and the West Tallinn Central Hospital (*3*). All participants in these subgroups were offered complete andrological workup at the AC-TUH; thus, 810 men (of 823) underwent sperm analysis. Further clinical phenotyping details are provided in **Supplemental Data**.

The subgroup of 'REPROMETA proven fathers' (n=311) was recruited in 2006-2011 at the Women's Clinic at Tartu University Hospital during the REPROMETA study (PI: M. Laan), originally designed to collect mother-father-placenta trios at delivery to investigate genetics of pregnancy complications (*43, 44*). In this study, the REPROMETA fathers represented reference men with proven fertility. Only self-reported age and BMI data were available for this subgroup.

383

384 Genotyping Y-chromosomal microdeletions

All study subjects (n=2,324) were typed for complete *AZFa* (loss of markers sY84 and sY86), *AZFb* (sY127 and sY134), *AZFc* (sY254 and sY255), and partial *AZFc* deletions *gr/gr* (sY1291), *b2/b3* (sY1191) and *b1/b3* (sY1161, sY1191 and sY1291) following established multiplex PCR protocols and

388 PCR primers (7, 45) (Table S15).

389

390 Re-sequencing of retained DAZ, BPY2 and CDY genes using Illumina MiSeq

391 Re-sequencing of the exonic regions of the retained AZFc genes (according to Ensembl release 84) in 392 476 cases with either gr/gr or b2/b3 deletions targeted in total 94,188 bp per subject. CDY, BPY2 and 393 DAZ genes were amplified using eight, ten or 26 PCR primer pairs, respectively (Table S16-S17). The 394 presence of all amplicons was confirmed using gel electrophoresis. Amplicons were pooled in 395 equimolar concentrations, barcoded per sample, and sequenced (250 bp reads, paired-end) on Illumina 396 MiSeq with at least $40 \times$ coverage. BWA (v0.7.15) (46) was implemented to map the sequencing reads 397 to a modified human genome reference (GRChg38), where CDY1a, CDY2a, BPY2a and either DAZ3-398 DAZ4 (gr/gr carriers) or DAZ1-DAZ2 (b2/b3 carriers) remained unchanged, but the sequences of other 399 CDY, BPY2 and DAZ gene copies were replaced with 'Ns'. SNVs and indels were identified using

GATK HaplotypeCaller (v3.7) with a minimum base quality 20 and outputting all sites (47). Ychromosomal phylogenetic markers were called using bcftools (v1.8) with minimum base quality 20,
mapping quality 20 and defining ploidy as 1.

403 Re-sequencing included 31 patients and 9 reference men with AZFc gr/gr deletions. Six men carrying

404 *gr/gr* deletions were not analyzed due to DNA limitations (2 cases) or unavailable andrological data (4

405 cases). The analysis of *b2/b3* deletion carriers included 382 patients (haplogroup N3: n=380; non-N3,

406 n=2) and 54 'Partners of pregnant women' (N3: n=53; non-N3, n=1).

407

408 Y-chromosomal haplogroup typing

Y lineages of the *gr/gr* samples were defined using 14 markers included in the re-sequencing, plus 34
additional markers determined by Sanger sequencing or restriction fragment length polymorphism
(RFLP) analysis (Table S17-S18). The *b2/b3*-deletion carriers were typed for Y marker N3-M46 (Tat)
(*48*). The sub-lineages of the re-sequenced haplogroup N3 samples were defined in more detail using
16 phylogenetic markers from the Illumina MiSeq dataset, following established nomenclature (*22, 49*).
For the other haplogroups, nomenclature according to the International Society of Genetic Genealogy
(ISOGG, version 14.14) was followed.

416

417 Determination of *DAZ*, *BPY2* and *CDY* gene dosage and gene types

418 The Bio-Rad QX 200 Droplet Digital PCR system was used to quantify the copy numbers of the retained 419 DAZ, BPY2 and CDY genes for 44 gr/gr deletion carriers (31 cases, 13 reference men with sperm 420 analysis data) and 631 b2/b3 carriers (382 cases/249 reference men). PCR primers and probes for gene 421 copy dosage detection are provided in Table S19 and methodological details in Supplemental Data. 422 The re-sequencing data of the DAZ genes covered nine paralogous sequence variants (PSVs) that were 423 used to determine the retained gene copies in the gr/gr and b2/b3 deletion carriers (**Table S20**). For the 424 validation of the DAZ gene copy mapping approach, at least five gr/gr carriers were additionally typed 425 for published SNV combinations differentiating the DAZ gene copies (23, 50). The retained CDYI gene

426 was identified according to Machev et al. (23).

427

428	Genetic association testing with andrological parameters
429	Statistical testing for the associations between AZFc gr/gr or b2/b3 deletions and andrological
430	parameters was conducted using RStudio (version 1.2.1335) and data were visualised using ggplot2
431	(version 3.2.1) (51). Differences in continuous clinical variables between groups were compared using
432	the non-parametric Pairwise Wilcoxon Rank Sum Test. Genetic association with the carrier status of
433	<i>b2/b3</i> deletion and its subtypes was also tested using linear regression analyses (Supplemental Data).
434	
435	Supplemental Data
436	Supplemental Data include Supplemental Subjects and Methods, four figures and 20 tables.
437	
438	Acknowledgements
439	We thank all the patients for making this study possible. The clinical team at the Andrology Centre,
440	Tartu University Hospital is thanked for the professional phenotyping and assistance in patient
441	recruitment over many years. Mart Adler and Eve Laasik are specifically acknowledged for the

442 management of the Androgenetics Biobank, and all M.L. team members are thanked for their contributions to the DNA extractions. Our work was supported by the Wellcome Trust (098051). P.H. 443 444 and L.K. were supported by Estonian Research Council Grant PUT1036 and M.P. and O.P. by PUT181. 445 L.K., M.G., K.R. and M.L. were supported by Estonian Research Council Project IUT34-12, R.F. by 446 IUT24-1 and S.R. by IUT24-1 and MOBTT53. Establishment of the cohort of Estonian infertility 447 subjects was also supported by the EU through the European Regional Development Fund, project

- 448 HAPPY PREGNANCY, no. 3.2.0701.12-004 (M.L., M.P., K.R.).
- 449

450 **Author contributions**

- 451 P.H. conceived and M.P., Y.X., C.T-S. and M.L. supervised the study. M.P. lead, O.P. and P.K.
- 452 contributed critically to the patient recruitment, phenotyping and clinical data documentation. P.H.,
- 453 L.K. and E.A. performed experiments, P.H., L.K. and M.L. performed analyses. M.G., S.R. and R.F.
- 454 provided data and assisted with analyses. M.P., K.R., K.M. and M.L. provided DNA samples. P.H.,

455	C.T-S	Y.X.	M.L.	and M.A.J.	provided	resources.	P.H.	and M.L.	drafted	the	manuscri	pt w	vith
155	C.I D.,		1.1.1.	und 111.1 1.5.	provided	resources.	1.11.	und m.D.	aranca	une	manasen	pt 11	1111

- 456 contributions from all other authors. All authors contributed to the final interpretation of data and
- 457 critical reading of the manuscript.
- 458
- 459 **Declaration of Interests**
- 460 The authors declare no competing interests.
- 461

462 Data Availability:

- 463 Illumina MiSeq re-sequencing data are available through the European Genome-phenome Archive
- 464 (EGA, https://www.ebi.ac.uk/) under the accession number: EGAS00001002157

465

466 Web resources:

- 467 International Society of Genetic Genealogy (ISOGG) https://isogg.org
- 468 RStudio: <u>http://www.rstudio.com/</u>
- 469 Primer3plus: https://primer3plus.com
- 470 Ensembl: https://www.ensembl.org/
- 471 Variant Effect Predictor tool (VEP): https://www.ensembl.org/Tools/VEP

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

472 **References**

- A. Jungwirth, A. Giwercman, H. Tournaye, T. Diemer, Z. Kopa, G. Dohle, C. Krausz,
 I. European Association of Urology Working Group on Male, European Association
 of Urology guidelines on Male Infertility: the 2012 update. *Eur Urol* 62, 324-332
 (2012).
- J. Datta, M. J. Palmer, C. Tanton, L. J. Gibson, K. G. Jones, W. Macdowall, A.
 Glasier, P. Sonnenberg, N. Field, C. H. Mercer, A. M. Johnson, K. Wellings,
 Prevalence of infertility and help seeking among 15 000 women and men. *Hum Reprod* 31, 2108-2118 (2016).
- 481
 3. M. Punab, O. Poolamets, P. Paju, V. Vihljajev, K. Pomm, R. Ladva, P. Korrovits, M.
 482
 483
 483
 483
 484
 484
 485
 485
 485
 486
 486
 486
 487
 487
 488
 488
 488
 489
 489
 480
 480
 480
 480
 480
 481
 480
 481
 481
 481
 481
 482
 483
 484
 484
 484
 485
 485
 486
 486
 487
 487
 488
 488
 488
 488
 488
 488
 488
 488
 489
 489
 489
 480
 480
 480
 480
 480
 481
 481
 481
 481
 481
 481
 482
 483
 484
 484
 484
 484
 485
 485
 486
 487
 487
 487
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488</
- 484
 4. I. A. Olesen, A. M. Andersson, L. Aksglaede, N. E. Skakkebaek, E. Rajpert-de Meyts,
 485
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486<
- F. Tuttelmann, F. Werny, T. G. Cooper, S. Kliesch, M. Simoni, E. Nieschlag, Clinical
 experience with azoospermia: aetiology and chances for spermatozoa detection upon
 biopsy. *Int J Androl* 34, 291-298 (2011).
- 490 6. ASRM, Diagnostic evaluation of the infertile male: a committee opinion. *Fertil Steril*491 103, e18-25 (2015).
- 492 7. C. Krausz, L. Hoefsloot, M. Simoni, F. Tuttelmann, A. European Academy of, N.
 493 European Molecular Genetics Quality, EAA/EMQN best practice guidelines for
 494 molecular diagnosis of Y-chromosomal microdeletions: state-of-the-art 2013.
 495 Andrology 2, 5-19 (2014).
- 496 8. T. P. Kohn, J. R. Kohn, R. C. Owen, R. M. Coward, The Prevalence of Y497 chromosome Microdeletions in Oligozoospermic Men: A Systematic Review and
 498 Meta-analysis of European and North American Studies. *Eur Urol* 76, 626-636
 499 (2019).
- 9. P. J. Stahl, P. Masson, A. Mielnik, M. B. Marean, P. N. Schlegel, D. A. Paduch, A
 decade of experience emphasizes that testing for Y microdeletions is essential in
 American men with azoospermia and severe oligozoospermia. *Fertil Steril* 94, 17531756 (2010).
- T. Kuroda-Kawaguchi, H. Skaletsky, L. G. Brown, P. J. Minx, H. S. Cordum, R. H.
 Waterston, R. K. Wilson, S. Silber, R. Oates, S. Rozen, D. C. Page, The AZFc region of the Y chromosome features massive palindromes and uniform recurrent deletions in infertile men. *Nat Genet* 29, 279-286 (2001).
- 508 11. H. Skaletsky, T. Kuroda-Kawaguchi, P. J. Minx, H. S. Cordum, L. Hillier, L. G.
 509 Brown, S. Repping, T. Pyntikova, J. Ali, T. Bieri, A. Chinwalla, A. Delehaunty, K.
 510 Delehaunty, H. Du, G. Fewell, L. Fulton, R. Fulton, T. Graves, S. F. Hou, P. Latrielle,
- 511 S. Leonard, E. Mardis, R. Maupin, J. McPherson, T. Miner, W. Nash, C. Nguyen, P.
- 512 Ozersky, K. Pepin, S. Rock, T. Rohlfing, K. Scott, B. Schultz, C. Strong, A. Tin-
- Wollam, S. P. Yang, R. H. Waterston, R. K. Wilson, S. Rozen, D. C. Page, The malespecific region of the human Y chromosome is a mosaic of discrete sequence classes. *Nature* 423, 825-U822 (2003).
- 516 12. S. Repping, H. Skaletsky, L. Brown, S. K. van Daalen, C. M. Korver, T. Pyntikova,
 517 T. Kuroda-Kawaguchi, J. W. de Vries, R. D. Oates, S. Silber, F. van der Veen, D. C.
 518 Page, S. Rozen, Polymorphism for a 1.6-Mb deletion of the human Y chromosome
 519 persists through balance between recurrent mutation and haploid selection. *Nat Genet*520 35, 247-251 (2003).

521	13.	S. Repping, S. K. van Daalen, C. M. Korver, L. G. Brown, J. D. Marszalek, J.
522		Gianotten, R. D. Oates, S. Silber, F. van der Veen, D. C. Page, S. Rozen, A family of
523		human Y chromosomes has dispersed throughout northern Eurasia despite a 1.8-Mb
524	1 /	deletion in the azoospermia factor c region. <i>Genomics</i> 83 , 1046-1052 (2004).
525	14.	S. G. Rozen, J. D. Marszalek, K. Irenze, H. Skaletsky, L. G. Brown, R. D. Oates, S. J.
526		Silber, K. Ardlie, D. C. Page, AZFc deletions and spermatogenic failure: a
527 528		population-based survey of 20,000 Y chromosomes. <i>Am J Hum Genet</i> 91 , 890-896
528 529	15	(2012). S. Formandas, S. Barasshini, L. H. Mayor, C. Floridia, C. Tyler, Smith, B. H. Mast, A.
529 530	15.	S. Fernandes, S. Paracchini, L. H. Meyer, G. Floridia, C. Tyler-Smith, P. H. Vogt, A large AZFc deletion removes DAZ3/DAZ4 and nearby genes from men in Y
530		haplogroup N. Am J Hum Genet 74 , 180-187 (2004).
532	16.	S. K. Bansal, D. Jaiswal, N. Gupta, K. Singh, R. Dada, S. N. Sankhwar, G. Gupta, S.
533	10.	Rajender, Gr/gr deletions on Y-chromosome correlate with male infertility: an
534		original study, meta-analyses, and trial sequential analyses. <i>Sci Rep</i> 6 , 19798 (2016).
535	17.	C. Krausz, C. Giachini, Y. Xue, M. K. O'Bryan, J. Gromoll, E. Rajpert-de Meyts, R.
536	17.	Oliva, I. Aknin-Seifer, E. Erdei, N. Jorgensen, M. Simoni, J. L. Ballesca, R. Levy, G.
537		Balercia, P. Piomboni, E. Nieschlag, G. Forti, R. McLachlan, C. Tyler-Smith,
538		Phenotypic variation within European carriers of the Y-chromosomal gr/gr deletion is
539		independent of Y-chromosomal background. <i>J Med Genet</i> 46 , 21-31 (2009).
540	18.	C. M. de Carvalho, L. W. Zuccherato, M. Fujisawa, T. Shirakawa, A. K. Ribeiro-dos-
541		Santos, S. E. Santos, S. D. Pena, F. R. Santos, Study of AZFc partial deletion gr/gr in
542		fertile and infertile Japanese males. J Hum Genet 51, 794-799 (2006).
543	19.	L. S. Teitz, T. Pyntikova, H. Skaletsky, D. C. Page, Selection Has Countered High
544		Mutability to Preserve the Ancestral Copy Number of Y Chromosome Amplicons in
545		Diverse Human Lineages. Am J Hum Genet 103, 261-275 (2018).
546	20.	S. K. Bansal, G. Gupta, S. Rajender, Y chromosome b2/b3 deletions and male
547		infertility: A comprehensive meta-analysis, trial sequential analysis and systematic
548		review. Mutat Res Rev Mutat Res 768, 78-90 (2016).
549	21.	S. Colaco, D. Modi, Genetics of the human Y chromosome and its association with
550		male infertility. Reprod Biol Endocrinol 16, 14 (2018).
551	22.	A. M. Ilumae, M. Reidla, M. Chukhryaeva, M. Jarve, H. Post, M. Karmin, L. Saag, A.
552		Agdzhoyan, A. Kushniarevich, S. Litvinov, N. Ekomasova, K. Tambets, E. Metspalu,
553		R. Khusainova, B. Yunusbayev, E. K. Khusnutdinova, L. P. Osipova, S. Fedorova, O.
554		Utevska, S. Koshel, E. Balanovska, D. M. Behar, O. Balanovsky, T. Kivisild, P. A.
555		Underhill, R. Villems, S. Rootsi, Human Y Chromosome Haplogroup N: A Non-
556		trivial Time-Resolved Phylogeography that Cuts across Language Families. Am J
557 558	22	Hum Genet 99, 163-173 (2016).
558 559	23.	N. Machev, N. Saut, G. Longepied, P. Terriou, A. Navarro, N. Levy, M. Guichaoua, C. Metzler-Guillemain, P. Collignon, A. M. Frances, J. Belougne, E. Clemente, J.
560		Chiaroni, C. Chevillard, C. Durand, A. Ducourneau, N. Pech, K. McElreavey, M. G.
561		Mattei, M. J. Mitchell, Sequence family variant loss from the AZFc interval of the
562		human Y chromosome, but not gene copy loss, is strongly associated with male
563		infertility. J Med Genet 41, 814-825 (2004).
564	24.	M. Ghorbel, S. Baklouti-Gargouri, R. Keskes, N. Chakroun, A. Sellami, F. Fakhfakh,
565	21.	L. Ammar-Keskes, gr/gr-DAZ2-DAZ4-CDY1b deletion is a high-risk factor for male
566		infertility in Tunisian population. Gene 592 , 29-35 (2016).
567	25.	C. Krausz, E. Casamonti, Spermatogenic failure and the Y chromosome. <i>Hum Genet</i>
568	- •	136 , 637-655 (2017).
569	26.	P. A. Underhill, G. D. Poznik, S. Rootsi, M. Jarve, A. A. Lin, J. Wang, B. Passarelli,
570		J. Kanbar, N. M. Myres, R. J. King, J. Di Cristofaro, H. Sahakyan, D. M. Behar, A.

571		Kushniarevich, J. Sarac, T. Saric, P. Rudan, A. K. Pathak, G. Chaubey, V. Grugni, O.
572		Semino, L. Yepiskoposyan, A. Bahmanimehr, S. Farjadian, O. Balanovsky, E. K.
573		Khusnutdinova, R. J. Herrera, J. Chiaroni, C. D. Bustamante, S. R. Quake, T.
574		Kivisild, R. Villems, The phylogenetic and geographic structure of Y-chromosome
575		haplogroup R1a. Eur J Hum Genet 23, 124-131 (2015).
576	27.	World Health Organization, WHO Laboratory Manual for the Examination and
577		Processing of Human Semen, 5th edn. (World Health Organization, Geneva, 2010).
578	28.	A. M. Andersson, N. Jorgensen, K. M. Main, J. Toppari, E. Rajpert-De Meyts, H.
579		Leffers, A. Juul, T. K. Jensen, N. E. Skakkebaek, Adverse trends in male reproductive
580		health: we may have reached a crucial 'tipping point'. Int J Androl 31, 74-80 (2008).
581	29.	M. A. Jobling, C. Tyler-Smith, Human Y-chromosome variation in the genome-
582		sequencing era. Nat Rev Genet 18, 485-497 (2017).
583	30.	P. Hallast, P. Balaresque, G. R. Bowden, S. Ballereau, M. A. Jobling, Recombination
584		dynamics of a human Y-chromosomal palindrome: rapid GC-biased gene conversion,
585		multi-kilobase conversion tracts, and rare inversions. PLoS Genet 9, e1003666
586		(2013).
587	31.	S. Rozen, H. Skaletsky, J. D. Marszalek, P. J. Minx, H. S. Cordum, R. H. Waterston,
588		R. K. Wilson, D. C. Page, Abundant gene conversion between arms of palindromes in
589		human and ape Y chromosomes. <i>Nature</i> 423 , 873-876 (2003).
590	32.	B. Trombetta, F. Cruciani, Y chromosome palindromes and gene conversion. Hum
591		<i>Genet</i> 136 , 605-619 (2017).
592	33.	W. Shi, S. Louzada, M. Grigorova, A. Massaia, E. Arciero, L. Kibena, X. J. Ge, Y.
593		Chen, Q. Ayub, O. Poolamets, C. Tyler-Smith, M. Punab, M. Laan, F. Yang, P.
594		Hallast, Y. Xue, Evolutionary and functional analysis of RBMY1 gene copy number
595		variation on the human Y chromosome. <i>Hum Mol Genet</i> 28 , 2785-2798 (2019).
596	34.	C. Lu, F. Zhang, H. Yang, M. Xu, G. Du, W. Wu, Y. An, Y. Qin, G. Ji, X. Han, A.
597		Gu, Y. Xia, L. Song, S. Wang, L. Jin, X. Wang, Additional genomic duplications in
598		AZFc underlie the b2/b3 deletion-associated risk of spermatogenic impairment in Han
599		Chinese population. <i>Hum Mol Genet</i> 20 , 4411-4421 (2011).
600	35.	Y. Yang, M. Ma, L. Li, D. Su, P. Chen, Y. Ma, Y. Liu, D. Tao, L. Lin, S. Zhang,
601	50.	Differential effect of specific gr/gr deletion subtypes on spermatogenesis in the
602		Chinese Han population. Int J Androl 33 , 745-754 (2010).
603	36.	Y. W. Lin, L. C. L. Hsu, P. L. Kuo, W. J. Huang, H. S. Chiang, S. D. Yeh, T. Y. Hsu',
604	50.	Y. H. Yu, K. N. Hsiao, R. M. Cantor, P. H. Yen, Partial duplication at AZFc on the Y
605		chromosome is a risk factor for impaired spermatogenesis in Han Chinese in Taiwan.
606		Hum Mutat 28, 486-494 (2007).
607	37.	J. J. Ye, L. Ma, L. J. Yang, J. H. Wang, Y. L. Wang, H. Guo, N. Gong, W. H. Nie, S.
608	57.	H. Zhao, Partial AZFc duplications not deletions are associated with male infertility
609		in the Yi population of Yunnan Province, China. J Zhejiang Univ Sci B 14, 807-815
610		(2013).
611	38.	B. Yang, Y. Y. Ma, Y. Q. Liu, L. Li, D. Yang, W. L. Tu, Y. Shen, Q. Dong, Y. Yang,
612	50.	Common AZFc structure may possess the optimal spermatogenesis efficiency relative
613		to the rearranged structures mediated by non-allele homologous recombination. <i>Sci</i>
614		Rep 5, 10551 (2015).
615	39.	C. Giachini, I. Laface, E. Guarducci, G. Balercia, G. Forti, C. Krausz, Partial AZFc
616	5).	deletions and duplications: clinical correlates in the Italian population. <i>Hum Genet</i>
617		124 , 399-410 (2008).
618	40.	D. Lo Giacco, C. Chianese, J. Sanchez-Curbelo, L. Bassas, P. Ruiz, O. Rajmil, J.
619	10.	Sarquella, A. Vives, E. Ruiz-Castane, R. Oliva, E. Ars, C. Krausz, Clinical relevance

620		of Y-linked CNV screening in male infertility: new insights based on the 8-year
621		experience of a diagnostic genetic laboratory. <i>Eur J Hum Genet</i> 22 , 754-761 (2014).
622	41.	M. J. Noordam, G. H. Westerveld, S. E. Hovingh, S. K. van Daalen, C. M. Korver, F.
623		van der Veen, A. M. van Pelt, S. Repping, Gene copy number reduction in the
624		azoospermia factor c (AZFc) region and its effect on total motile sperm count. <i>Hum</i>
625		<i>Mol Genet</i> 20 , 2457-2463 (2011).
626	42.	M. Grigorova, M. Punab, K. Ausmees, M. Laan, FSHB promoter polymorphism
627		within evolutionary conserved element is associated with serum FSH level in men.
628		<i>Hum Reprod</i> 23 , 2160-2166 (2008).
629	43.	T. Kikas, R. Inno, K. Ratnik, K. Rull, M. Laan, C-allele of rs4769613 near FLT1
630		represents a high-confidence placental risk factor in preeclampsia. <i>Hypertension</i> , (in
631		press).
632	44.	D. Pilvar, M. Reiman, A. Pilvar, M. Laan, Parent-of-origin-specific allelic expression
633		in the human placenta is limited to established imprinted loci and it is stably
634		maintained across pregnancy. <i>Clin Epigenetics</i> 11 , 94 (2019).
635	45.	Y. W. Lin, C. L. Hsu, P. H. Yen, A two-step protocol for the detection of
636		rearrangements at the AZFc region on the human Y chromosome. <i>Molecular Human</i>
637		<i>Reproduction</i> 12 , 347-351 (2006).
638	46.	H. Li, R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler
639		transform. <i>Bioinformatics</i> 25, 1754-1760 (2009).
640	47.	A. McKenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytsky, K.
641		Garimella, D. Altshuler, S. Gabriel, M. Daly, M. A. DePristo, The Genome Analysis
642		Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing
643		data. Genome Res 20, 1297-1303 (2010).
644	48.	T. Zerjal, B. Dashnyam, A. Pandya, M. Kayser, L. Roewer, F. R. Santos, W.
645		Schiefenhovel, N. Fretwell, M. A. Jobling, S. Harihara, K. Shimizu, D. Semjidmaa,
646		A. Sajantila, P. Salo, M. H. Crawford, E. K. Ginter, O. V. Evgrafov, C. Tyler-Smith,
647		Genetic relationships of Asians and Northern Europeans, revealed by Y-chromosomal
648		DNA analysis. Am J Hum Genet 60, 1174-1183 (1997).
649	49.	M. Karmin, L. Saag, M. Vicente, M. A. Wilson Sayres, M. Jarve, U. G. Talas, S.
650		Rootsi, A. M. Ilumae, R. Magi, M. Mitt, L. Pagani, T. Puurand, Z. Faltyskova, F.
651		Clemente, A. Cardona, E. Metspalu, H. Sahakyan, B. Yunusbayev, G. Hudjashov, M.
652		DeGiorgio, E. L. Loogvali, C. Eichstaedt, M. Eelmets, G. Chaubey, K. Tambets, S.
653		Litvinov, M. Mormina, Y. Xue, Q. Ayub, G. Zoraqi, T. S. Korneliussen, F. Akhatova,
654		J. Lachance, S. Tishkoff, K. Momynaliev, F. X. Ricaut, P. Kusuma, H.
655		Razafindrazaka, D. Pierron, M. P. Cox, G. N. Sultana, R. Willerslev, C. Muller, M.
656		Westaway, D. Lambert, V. Skaro, L. Kovacevic, S. Turdikulova, D. Dalimova, R.
657		Khusainova, N. Trofimova, V. Akhmetova, I. Khidiyatova, D. V. Lichman, J.
658		Isakova, E. Pocheshkhova, Z. Sabitov, N. A. Barashkov, P. Nymadawa, E. Mihailov,
659		J. W. Seng, I. Evseeva, A. B. Migliano, S. Abdullah, G. Andriadze, D. Primorac, L.
660		Atramentova, O. Utevska, L. Yepiskoposyan, D. Marjanovic, A. Kushniarevich, D.
661		M. Behar, C. Gilissen, L. Vissers, J. A. Veltman, E. Balanovska, M. Derenko, B.
662		Malyarchuk, A. Metspalu, S. Fedorova, A. Eriksson, A. Manica, F. L. Mendez, T. M.
663		Karafet, K. R. Veeramah, N. Bradman, M. F. Hammer, L. P. Osipova, O. Balanovsky,
664		E. K. Khusnutdinova, K. Johnsen, M. Remm, M. G. Thomas, C. Tyler-Smith, P. A.
665		Underhill, E. Willerslev, R. Nielsen, M. Metspalu, R. Villems, T. Kivisild, A recent
666		bottleneck of Y chromosome diversity coincides with a global change in culture.
667		<i>Genome Res</i> 25 , 459-466 (2015).
668	50.	S. Fernandes, K. Huellen, J. Goncalves, H. Dukal, J. Zeisler, E. Rajpert De Meyts, N.
669		E. Skakkebaek, B. Habermann, W. Krause, M. Sousa, A. Barros, P. H. Vogt, High

- 670 frequency of DAZ1/DAZ2 gene deletions in patients with severe oligozoospermia.
- Mol Hum Reprod 8, 286-298 (2002). 671
- H. Wickham, ggplot2: Elegant Graphics for Data Analysis (Use R!, Springer-Verlag 672 51. New York, New York, 2009). 673

674 675

Figures and legends 676



677

678 Figure 1. Y-chromosomal *AZFc* region and its partial deletions in the study group.

679 (A) Schematic representation of the human Y chromosome with the AZFa, AZFb and AZFc regions 680 shown as black bars.

681 **(B)** Magnified structure of the *AZFc* region with approximate locations of multi-copy protein-coding 682 genes, STS (sY) markers for the detection of AZFc partial deletions and the span of typical gr/gr and 683 b2/b3 deletions (10). P1-P3 (gray triangles) denote palindromic genomic segments consisting of two 'arms' representing highly similar inverted DNA repeats (>99.7% sequence identity) that flank a 684 685 relatively short distinct 'spacer' sequence. Of note, the occurrence of the b2/b3 deletion requires a 686 preceding inversion in the AZFc region and therefore its presentation on the reference sequence includes 687 also the retained segment (gray dashed line). Full details about alternative gr/gr and b2/b3 deletion 688 types are presented in Figure S1.

- 689 (C) Dosage of multi-copy genes on human Y chromosomes with or without *AZFc* deletions.
- (D) Prevalence of the gr/gr and b2/b3 deletions detected in the subgroups of this study. Fisher's exact
- 691 test was used to test the statistical significance in the deletion frequencies between the groups.
- 692 PAR, pseudoautosomal region; MSY, male-specific region of the Y chromosome; cen, centromere;
- 693 *AZF*, azoospermia factor region.
- 694

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .





695



697 (A) Y-chromosomal lineages indicated with typed terminal markers (left), deleted (white)/retained 698 (black) DAZ and CDYI gene copies (middle) and secondary rearrangements in the AZFc region (right) 699 of idiopathic male factor infertility (n=31) and reference cases (n=13) carrying the gr/gr deletion. The 690 human Y-chromosomal reference sequence has four DAZ and two CDYI copies; the retained gene

701 copies on each Y chromosome with a gr/gr deletion are shown as filled boxes. Chromosomes carrying 702 atypical *gr/gr* subtypes with the loss of either the *DAZ1/DAZ3* or *DAZ2/DAZ4* gene pair due to complex 703 genomic rearrangement combining the previous r2/r3 inversion with a subsequent gr/gr deletion, are 704 highlighted with a dashed gray square. 705 (B) Enrichment of the Y-chromosomal lineage R1a1-M458 and its sub-lineages in study subjects 706 carrying the gr/gr deletion in comparison to the Estonian general population (data from (26)). Fisher's 707 exact test was used to test the statistical significance between the groups. 708 (C) Y-chromosomal lineages indicated with typed terminal markers (left) and the copy number of the 709 DAZ, BPY2 and CDY1 gene copies (right) determined for 382 idiopathic male factor infertility cases 710 carrying the *b2/b3* deletion. The light gray box denotes *DAZ*, *BPY2* and *CDY1* gene dosage consistent

- 711 with full b2/b4 duplication(s). The legend for the deletion subtype is shown in the bottom right corner.
- 712 Further information on the distribution of Y-chromosomal lineages in the carriers of AZFc partial
- 713 deletions are provided in Tables S5-S6 and the *AZFc* rearrangement types are detailed in Figure S1
- 714 and Tables S7-S11. n, number; n.a., not available; Ref, reference cases
- 715



716

717 Figure 3. Complex structural variants at the Y-chromosomal lineage R1a1-M458 and their effect

718 on andrological parameters.

- 719 (A) Schematic presentation of the Y chromosome with the r2/r3 inversion compared to the reference
- 720 sequence. The r2/r3 inversion structure nearly destroys the large palindrome P1 and, consequently,

destabilizes the *AZFc* region since several long DNA amplicons with highly similar DNA sequence (*b2*, *b3* and *b4*; *g2* and *g3*; *y1* and *y3*) are positioned in the same sequence orientation. This structure promotes non-allelic homologous recombination mediating recurrent deletion and duplication events. The approximate regions removed by the identified *gr/gr* and *b2/b3* deletions arising on the *r2/r3* inverted Y chromosome are shown as dashed lines.

726 **(B)** Distribution of andrological parameters in the idiopathic male factor infertility cases (total sperm 727 counts $0 - 39 \times 10^6$) subgrouped based on the structure of the AZFc region. The median (5–95% range) 728 of each parameter is shown for cases carrying the r2/r3 inversion plus secondary deletions compared to 729 infertile men without any AZFc deletion. The Pairwise Wilcoxon Rank sum test was applied to estimate 730 the statistical difference between groups. Threshold values (shown in blue) for sperm parameters 731 corresponding to severe spermatogenic failure are based on international guidelines (27). For 732 reproductive hormones, reference values of the laboratory service provider are shown. The empirical 733 threshold for the total testis volume was based on routinely applied clinical criteria at the AC-TUH. For

full details see Table S3 and Table S11.

735 (C) The majority of idiopathic infertility cases carrying the r2/r3 inversion plus secondary *AZFc* partial 736 deletions (total n=10) exhibit severe oligoasthenoteratozoospemia (OAT) defined as extremely reduced 737 sperm counts (<5 x 10⁶/ml) and concentration (<10 x 10⁶/ejaculate) combined with low fraction of 738 sperms with normal morphology (<4% normal forms) and motility (<32% progressive motile 739 spermatozoa). Reference values for andrological parameters have been applied as referred in sub-figure 740 B. As total testis volume is mostly within the expected range, their infertility is not caused by intrinsic 741 congenital testicular damage but rather due to severe spermatogenic failure *per se*.

742 Del, deletion, inv, inversion, dupl, duplication, n, number; sec, secondary, mill, million, ej., ejaculate

743

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .







Tables

		Idiopathic spermatogenic impairment (n=1,190) ^a			U 1	Reference groups (n=1,134)		
		Azoo-/ crypto-	Severe oligo-	Moderate oligo-	Partners of	Estonian young	REPROMETA	
Parameter	Unit	zoospermia	zoospermia	zoospermia	pregnant women ^b	men cohort ^c	proven fathers	
	n	104/88	319	679	324	499	311	
Age	years	33.2	32.2	31.7	31.0	18.6	31.0	
		(23.6-51.8)	(23.9-49.5)	(23.0-44.6)	(22.9-45.0)	(17.2-22.9)	(21.0-43.0)	
BMI	kg/m ²	26.0	25.9	25.8	24.8	22.0	25.9	
	-	(21.2 - 34.4)	(20.2-35.5)	(20.1-34.6)	(20.0-32.2)	(18.7-27.5)	(20.2-33.1)	
Total testis volume	mL	33.5	39.0	40.0	46.0	50.0	n.d.	
		(17.0-49.0)	(22.0-50.0)	(26.0-52.0)	(34.0-62.4)	(35.0-70.0)		
Semen volume	mL	3.3	3.3	3.6	3.7	3.2	n.d.	
		(0.8-6.6)	(1.1-7.0)	(1.6-6.9)	(1.7-8.0)	(1.2-6.4)		
Sperm	x 10 ⁶ /mL	0	1.4	6.0	76.0	66.8	n.d.	
concentration		(0-0.2)	(0.4-5.2)	(2.2-15.2)	(16.7-236.0)	(8.2-225.1)		
Total sperm count	x 10 ⁶ /	0	4.7	23.1	295.2	221.6	n.d.	
*	ejaculate	(0-0.7)	(1.3-9.3)	(11.0-37.5)	(60.0-980.1)	(18.4-788.0)		
Progressive A+B	%	0	16.0	27.0	50.0	57.3	n.d.	
motility		(0-37.2)	(0-47.2)	(1.0-57.0)	(30.0-69.0)	(34.7-75.3)		
Sperms with	%	0	0	2.0	10.0	12.0	n.d.	
normal morphology		(0-1.0)	(0-6.0)	(0-9.0)	(2.0-19.1)	(4.0-20.0)		
FSH	IU/L	13.7	6.6	5.2	3.6	2.8	n.d.	
		(2.7-38.2)	(1.9-22.8)	(1.8-16.5)	(1.5-8.3)	(1.2-6.7)		
LH	IU/L	5.7	4.6	4.2	3.6	3.8	n.d.	
		(2.1-12.0)	(1.9-9.9)	(1.8-8.4)	(1.5-6.7)	(1.8-7.2)		
Total testosterone	nmol/L	15.3	16.6	16.6	16.5	27.7	n.d.	
		(7.7-28.4)	(7.9-30.0)	(8.5-30.3)	(8.8-27.2)	(15.4-46.3)		

Table 1. Characteristics of the patients with male factor infertility and reference groups used for comparison.

All study subjects were recruited in Estonia. For each parameter, median and (5th-95th %) percentile values are shown. Additional details in Table S1.

^a Patients were subgrouped based on total sperm counts per ejaculate: azoospermia, no sperm; cryptozoospermia, sperm counts $>0 - 1 \times 10^6$; severe oligozoospermia, $>1 - 10 \times 10^6$; moderate oligozoospermia, $>10-39 \times 10^6$ (3).

^b Male partners of pregnant women (3); eight men had sperm counts $< 39 \times 10^6$; for four men sperm analysis was not available.

^c Male cohort without fatherhood data (42); 47 men had sperm counts $< 39 \times 10^6$; for nine men sperm analysis was not available

^d REPROMETA study recruited and sampled couples after delivery of their newborn; details in (43, 44).

n.d., not determined

	Idiopathic male infertility	1						
Y-chromosomal rearrangements	patients (n)	Reference men (n)						
All analyzed cases	1,190	1,134						
Any AZFc gr/gr deletion	32 (2.7%)	14 (1.2%)						
, , , , , , , , , , , , , , , , , , , ,		016; $\overrightarrow{OR} = 2.2$ [95% CI 1.2–4.2]						
Any AZFc b2/b3 deletion	388 (32.6%)	367 (32.4%)						
Other type of AZF deletion	Loss of <i>b2/b3</i> marker	$AZFc \ b1/b3 \ del \ (1 \ case);$						
	sY1191 (1 case)	partial AZFa del (1 case)						
No deletion	769 (64.6%)	751 (66.2%)						
Simple partial AZFc deletions								
Typical gr/gr deletion	19/31 (61.3%)	8/13 (61.5%)						
Typical $b2/b3$ deletion ^{<i>a</i>}	300/382 (78.5%)	210/249 (84.3%)						
AZFc partial deletion followed by b.	2/h4 duplication							
gr/gr del + $b2/b4$ dupl ^b	2/31 (6.5%)	3/13 (23.1%)						
		144; OR = 0.2 [95% CI 0.0-1.6]						
b2/b3 del + $b2/b4$ dupl ^{a,b}	78/382 (20.4%)	34/249 (13.7%)						
	· · · · · · · · · · · · · · · · · · ·	026; OR = 1.6 [95% CI 1.0-2.4]						
AZFc partial deletion and atypical g	genomic rearrangements ^c							
gr/gr del + extra gene copies	1	0						
b2/b3 del + extra gene copies	3	4						
Complex events on the Y lineage R1	a1-M458 with the preceding	AZFc r2/r3 inversion						
r2/r3 inv + gr/gr del	8	, 2 ^d						
r2/r3 inv + gr/gr del + $b2/b4$ dupl	1	0						
r2/r3 inv + loss of marker sY1191	1	0						
+ secondary gene duplications ^e								
r2/r3 inv + $b2/b3$ del + $b2/b4$ dupl	0	1^{f}						
Carriers of any AZFc gr/gr deletion type without the preceding r2/r3 inversion								
gr/gr del w/o detected $r2/r3$ inv	23/1,190 (1.9 %)							
6 6 ·····		090; OR = 1.8 [95% CI 0.9-3.7]						
Deletion subtype analysis was carried								

Table 2. Summary of the identified Y-chromosomal AZF deletion subtypes.

^a Deletion subtype analysis was carried out for cases with available sufficient quantities of DNA. REPROMETA subjects were excluded from the b2/b3 deletion subtype analysis and subsequent statistical testing due to missing andrological data.

^b One or more amplicons of the retained '2xDAZ, 2xBPY2, 1xCDY1' (gr/gr deletion) or '2xDAZ, 1xBPY2, 1xCDYI' (b2/b3 deletion) genes

^c additional copies of *DAZ*, *BPY2* and/or *CDY1* genes inconsistent with the full '*b2/b4*' duplication ^d Including one REPROMETA man without andrological data

^e detected gene copy numbers 6xDAZ, 4xBPY2, 3xCDY1; the obligate presence of r2/r3 inversion was defined based on Y-chromosomal phylogeny as the man carries Y lineage R1a1a1b1a1a1c-CTS11962.1 that was also identified in two cases with the r2/r3 inversion (Table S11).

^f Man from 'Partners of pregnant women' cohort with sperm concentration 12 x 10⁶ /ml below normozoospermia threshold (15 x 10⁶ /ml) and sperm counts 39.4 x 10⁶/ejaculate at the borderline of the lowest reference value (39.0 x 10⁶/ejaculate)

		AZFc r2/r3 inversion + AZFc partial deletion					
		Estimated non-	Detected	% of carriers in			
Group	All (n)	carriers (n)	carriers (n)	the (sub)group			
a. Full study group							
All analyzed study subjects	2,324	2,311	13	0.6%			
Study subjects with sperm counts	2,000	1,988	12	0.6%			
Subjects stratified based on total speri	n counts p	er ejaculate					
Sperm counts $0 - 10 \ge 10^6$	524	515	9	1.7%			
Sperm counts $>10 \times 10^6$	1,476	1,473	3	0.2%			
-		Fisher's exact tes	st, $p = 6.0 \ge 10$	$^{-4}$, OR = 8.6 [95%]			
		CI 2.3–31.8]	•				
b. Carriers of the Y lineage R1a1a-M4	158^a						
In all analyzed study subjects	119	106	13	11.0%			
In study subjects with sperm counts	102	90	12	11.8%			
Subjects stratified based on total speri	n counts p	er ejaculate					
Sperm counts $0 - 10 \ge 10^6$	27	18	9	33.7%			
Sperm counts $>10 \times 10^6$	75	72	3	4.0%			
		Fisher's exact tes	st, $p = 3.0 \ge 10$	$^{-4}$, OR = 12.0			
		[95% CI 2.9–48.					

Table 3. Enrichment of the AZFc r2/r3 inversion followed by a partial AZFc deletion in men with severe spermatogenic failure

^a expected number of Y lineage R1a1-M458 in each subgroup was estimated using the known Estonian population prevalence 5.1% (26)

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplemental Subjects and Methods

Details on the clinical assessment of the study subjects

All men, who had turned to Andrology Centre, Tartu University Hospital (AC-TUH) due to idiopathic infertility (n=1,190), as well as the participants of the 'Estonian young men' cohort (n=499) and the subgroup 'Partners of pregnant women' (n=324) were offered complete routine andrological workup. The subjects were examined by specialist andrologists at the AC-TUH, who had received respective training in clinical assessment and standardized andrological workup, locally and in collaboration with other European Andrology Academy (EAA) accredited centers. Also, anthropometric parameters were documented during clinical examination. Details are described in (*1*).

Physical examination for the assessment of genital pathology and testicular size (orchidometer; made of birch wood, Pharmacia & Upjohn, Denmark) was performed with the patients in standing position. The total testes volume is the sum of right and left testicles. The position of the testicles in the scrotum, pathologies of the genital ducts (epididymis and ductus deference) and the penis, urethra, presence and if applicable grade of varicocele were registered for each subject.

For 2,000 study subjects sperm analysis was performed, whereas 13 reference cases did not agree with this procedure. Semen samples were obtained by patient masturbation and semen analysis was performed in accordance with the World Health Organization (WHO) recommendations. In brief, after ejaculation, the semen was incubated at 37° C for 30–40 min for liquefaction. Semen volume was estimated by weighing the collection tube with the semen sample and subsequently subtracting the predetermined weight of the empty tube assuming 1 g = 1 mL. For assessment of the spermatozoa concentration, the samples were diluted in a solution of 0.6 mol,L NaHCO3 and 0.4% (v,v) formaldehyde in distilled water. The spermatozoa concentration was assessed using the improved Neubauer haemocytometers.

Genomic DNA was extracted from EDTA-blood. After blood draw in the morning, serum and plasma fractions were separated immediately for hormone measurements (FSH, LH, testosterone). All laboratory analyses and routine genetic testing (karyotyping, Y-chromosomal microdeletions) were performed at the United Laboratories of Tartu University Hospital according to the established clinical laboratory guidelines. Detailed methodology and reference values for hormonal levels are available by the service provider: https://www.kliinikum.ee/yhendlabor/analueueside-taehestikuline-register.

Analysis of variant effects from the Illumina MiSeq dataset

Variant effect prediction was performed using the Variant Effect Predictor tool (VEP, https://www.ensembl.org/Tools/VEP, Ensembl release 99) (2). The Combined Annotation Dependent Depletion (CADD) score ≥ 20 , i.e., including variants among the top 1% of deleterious variants in the human genome, was considered indicative of potential functional importance of identified SNVs in the coding regions (3).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

DAZ, BPY2 and CDY copy number detection using Droplet Digital PCR

The PCR primers and probes were designed using Primer3plus (version 2.4.2), PCR reactions were performed according to the recommendations in the Droplet Digital PCR Application Guide (Bio-Rad, U.S.) (**Table S19**) and described in (*4*). A XQ200 Droplet Reader was used to measure the fluorescence of each droplet and QuantaSoft software (v1.6.6.0320; Bio-Rad) to cluster droplets into distinct fluorescent groups. The copy number of each gene was determined by calculating the ratio of target (unknown - *DAZ*, *BPY2* or *CDY*) and reference (single-copy *SRY* gene) concentration.

ddPCR reactions for each gene were performed once for every sample. For samples carrying the *gr/gr* deletion, if the copy number obtained differed from the expected (two copies of *DAZ* and *BPY2*, three copies of *CDY*), then the ddPCR reaction was repeated. For *b2/b3* carriers typing was repeated for all samples not carrying the two most typical copy numbers (2-1-3 or 4-2-4 copies of *DAZ*, *BPY2* and *CDY* genes, respectively). Additionally, a total of 5% of random samples were replicated. If the copy number estimates between replicates differed by 0.8 or more, then a third replicate was performed, and the final copy number was calculated as average of the two closest replicates.

Genetic association analysis using linear regression

Genetic association with the carrier status of b2/b3 deletion and its subtypes was also tested using linear regression analyses adjusted for age. For sperm parameters abstinence time and for total testosterone levels BMI estimates were additionally used as cofactors. Natural log transformation was used to achieve an approximately normal distribution of values. In all cases (except total sperm counts), the applied transformation resulted in a close-to-normal distribution of values. For the linear regression analyses, statistical significance threshold after correction for multiple testing was estimated $P < 1.0 \times 10^{-3}$ (6 tests x 8 independent parameters).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Protocol for the detection of *AZFc* rearrangement at the Y lineage R1a1a1b1a1a-M458: *r2/r3* inversion followed by partial deletions

Step 1. Multiplex PCR for typing the *AZFc* partial deletions (modified from (5, 6)):

The most commonly used method to detect *AZFc* partial deletions is the plus/minus STSs-based PCR assay that detects the presence of five markers around *AZFc* region (Figure 1B, Table S2). The multiplex PCR reactions contained the final concentrations of 1X PCR buffer B1 (Solis Biodyne, Estonia), 2.5 mM MgCl₂, 2.5 mM dNTP, 2 μ M PCR primers for STS markers sY1291 and sY1201, 3 μ M PCR primers for STS markers sY1191, sY1206 and sY1161 (**Table S15**), 1U FIREPol[®] DNA polymerase (Solis Biodyne) and 10 ng of template genomic DNA per reaction. The following PCR conditions were used: for 5 min at 95°C, followed by 32 cycles of 30 sec at 95°C, 30 sec at 63°C and 1 min at 72°C, final extension of 10 min at 72°C and a 4°C hold. The presence/absence of PCR products in a reaction were checked on 2% agarose gel. Lack of amplification of STS marker sY1291 (but presence of all others) was used to determine the *gr/gr* deletion, and lack of sY1191 the *b2/b3* deletion.

Step 2. Analysis of the allelic state of Y lineage R1a1a1b1a1a-specific phylogenetic marker M458:

The phylogenetic marker M458 (rs375323198, A > G polymorphism, GRCh38 genomic coordinate: chrY: 22220317) indicating the carrier status of r2/r3 inverted Y chromosome was amplified using the following conditions: PCR reactions contained the final concentrations of 1X PCR buffer B1 (Solis Biodyne), 2.5 mM MgCl₂, 2.5 mM dNTP, 10 µM forward and reverse PCR primers for M458 (see **Table S18** for primer sequences), 1U FIREPol[®] DNA polymerase (Solis Biodyne OÜ) and 10 ng of template genomic DNA per reaction. The following PCR conditions were used: for 5 min at 95°C, followed by 32 cycles of 30 sec at 95°C, 30 sec at 52°C and 1 min at 72°C, final extension of 10 min at 72°C and a 4°C hold. The presence of the M458 marker in derived state (instead of the ancestral allele 'A' presence of allele 'G' at position 147) was determined using Sanger sequencing.

Step 3. Analysis of retained DAZ gene copies by typing gene-specific PSVs (optional):

The retained DAZ gene copies can be identified by typing gene copy-specific paralogous sequence variants (PSVs). In the current study, the retained DAZ copies were identified by determining the allelic states of 9 PSVs from the Illumina MiSeq re-sequencing data (see **Table S20** for full details). Additionally, a number of published protocols are available, for full details see (7-9).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure S1. The human Y chromosome and the Azoospermia Factor (AZF) regions.

(A.) The human Y chromosome drawn to approximate scale with regions of *AZFa*, *AZFb* and *AZFc* deletions shown below as black bars. PAR - pseudoautosomal region, MSY - male-specific region of the Y chromosome, cen - centromere, *AZF* - azoospermia factor region.

(B.) Structure of the AZFc region on human Y-chromosomal reference sequence with approximate locations of protein-coding genes and STS (sY) markers used for detection of partial AZFc deletions (10).

Alternative involved regions in gr/gr deletions arising on (C.) the human Y-chromosomal reference sequence and (D.) the Y chromosome with a preceding b3/b4 inversion. The approximate region removed by each deletion is shown as a dashed line.

(E.) Structure of the AZFc region undergone the gr/gr deletion and the proposed model of homologous recombination leading to the subsequent 'b2/b4' duplication. The light blue box denotes the recombination targets. The duplication is presumably the result of recombination between sister chromatids.

(F.) Reported models for b2/b3 deletions arising on the Y chromosomes with preceding b2/b3 or g1/g3 inversions. The approximate region removed by each deletion is shown as a dashed line.

(G.) Structure of the *AZFc* region undergone the b2/b3 deletion and the proposed model of homologous recombination leading to the subsequent 'b2/b4' duplication. The light blue box denotes the recombination targets. The duplication is presumably the result of recombination between sister chromatids.



Figure S2. Location of the identified exonic variants in the DAZ genes.

(A.) Schematic representation of the human Y-chromosomal reference sequence containing the AZFc region, with approximate locations of protein-coding genes and their direction of transcription shown as black triangles.

Direct and inverted repeats with highly similar DNA sequences are denoted as coloured arrows (b blue, t - teal, g - green, r - red, y - yellow as originally described by (10); arrow direction indicates the orientation of the gene from transcription start site.

(B.) The structure of human DAZ genes, modified from (7) to represent the human Y-chromosomal reference sequence (GRCh38). Blue dashed arrows show the direction of transcription. Exons with high DNA sequence similarity within and between DAZ genes are denoted with the same fill colour. The number of highly similar exon 7 copies (in yellow) varies between genes and copies marked with the same letter denote identical sequences.

Numbers below the gene structure denote exonic variants:

- 1 DAZ1 p.H173Y or DAZ2 p.H173Y
- 2 DAZ1 p.O262E or DAZ2 p.O262E
- 3 DAZ1 p.Y243C or DAZ2 p.Y219C
- 4 potential splicing variant in DAZ3 or DAZ4.

Black squares in DAZ4 denote the deleted exons 7f and 7y in Y lineages I1 and R1a1a1b1a2, respectively.



Figure S3. Distribution of seminal parameters in idiopathic male factor infertility cases with spermatogenic impairment and reference subjects.

Samples are grouped by genotype with the number of samples (n) shown in brackets, del - deletion, sec - secondary, inv - inversion, dupl - duplication, mill - million, ej. - ejaculate. Note different scaling of the Y-axis for the two study groups in panels B and C.



Figure S4. Distribution of hormonal and testicular parameters in idiopathic male factor infertility cases with spermatogenic impairment and reference individuals.

Samples are grouped by genotype with the number of samples (n) shown in brackets. del - deletion, sec - secondary, inv - inversion, dupl - duplication.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplemental references:

- 1. M. Punab, O. Poolamets, P. Paju, V. Vihljajev, K. Pomm, R. Ladva, P. Korrovits, M. Laan, Causes of male infertility: a 9-year prospective monocentre study on 1737 patients with reduced total sperm counts. *Hum Reprod* **32**, 18-31 (2017).
- 2. W. McLaren, L. Gil, S. E. Hunt, H. S. Riat, G. R. Ritchie, A. Thormann, P. Flicek, F. Cunningham, The Ensembl Variant Effect Predictor. *Genome Biol* **17**, 122 (2016).
- 3. P. Rentzsch, D. Witten, G. M. Cooper, J. Shendure, M. Kircher, CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res* **47**, D886-D894 (2019).
- W. Shi, S. Louzada, M. Grigorova, A. Massaia, E. Arciero, L. Kibena, X. J. Ge, Y. Chen, Q. Ayub, O. Poolamets, C. Tyler-Smith, M. Punab, M. Laan, F. Yang, P. Hallast, Y. Xue, Evolutionary and functional analysis of RBMY1 gene copy number variation on the human Y chromosome. *Hum Mol Genet* 28, 2785-2798 (2019).
- 5. Y. W. Lin, C. L. Hsu, P. H. Yen, A two-step protocol for the detection of rearrangements at the AZFc region on the human Y chromosome. *Molecular Human Reproduction* **12**, 347-351 (2006).
- C. Krausz, L. Hoefsloot, M. Simoni, F. Tuttelmann, A. European Academy of, N. European Molecular Genetics Quality, EAA/EMQN best practice guidelines for molecular diagnosis of Y-chromosomal microdeletions: state-of-the-art 2013. *Andrology* 2, 5-19 (2014).
- S. Fernandes, K. Huellen, J. Goncalves, H. Dukal, J. Zeisler, E. Rajpert De Meyts, N. E. Skakkebaek, B. Habermann, W. Krause, M. Sousa, A. Barros, P. H. Vogt, High frequency of DAZ1/DAZ2 gene deletions in patients with severe oligozoospermia. *Mol Hum Reprod* 8, 286-298 (2002).
- N. Machev, N. Saut, G. Longepied, P. Terriou, A. Navarro, N. Levy, M. Guichaoua, C. Metzler-Guillemain, P. Collignon, A. M. Frances, J. Belougne, E. Clemente, J. Chiaroni, C. Chevillard, C. Durand, A. Ducourneau, N. Pech, K. McElreavey, M. G. Mattei, M. J. Mitchell, Sequence family variant loss from the AZFc interval of the human Y chromosome, but not gene copy loss, is strongly associated with male infertility. *J Med Genet* 41, 814-825 (2004).
- 9. T. Vaszko, J. Papp, C. Krausz, E. Casamonti, L. Geczi, E. Olah, Discrimination of Deletion and Duplication Subtypes of the Deleted in Azoospermia Gene Family in the Context of Frequent Interloci Gene Conversion. *PLoS One* **11**, e0163936 (2016).
- T. Kuroda-Kawaguchi, H. Skaletsky, L. G. Brown, P. J. Minx, H. S. Cordum, R. H. Waterston, R. K. Wilson, S. Silber, R. Oates, S. Rozen, D. C. Page, The AZFc region of the Y chromosome features massive palindromes and uniform recurrent deletions in infertile men. *Nat Genet* 29, 279-286 (2001).